1. Annual report on the cause of death statistics in 2005. Korean National Statistical Office, 2006.

2. D’Agostino RB, Russell MW, Huse DM, EllisonRC, Silbershatz H, Wilson PWF et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272-81.

3. Sacco RL. Pathogenesis, classification and epidemiology of cerebrovascular disease. In Rowland (ed): Merritt’s Neurology 10th ed, Philadelphia: Lippincott Williams & Wilkins; 2000, p.217-29.

4. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681-9.

5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.

6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

7. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.

8. Kim JG, Song JH, Cho HI, Kim SI. Prevalence of hyperlipidemia and other risk factors associated with coronary artery disease in Koreans. Korean Clinical Pathology. 1991;11:341-7.

9. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol. 2001;87 :554-9.

10. Kim YS, Jung EA, Shin JE, Chung JC, Yang HK, Kim NJ et al. Daio-Orengedokuto inhibits HMGCoA reductase and pancreatic lipase. Biol. Pharm. Bull. 2002;25:1442-5.

11. Yang HK, Kim YS, Bae HS, Cho KH, Shin JE, Kim NJ et al., Rhei Rhizoma and chunghyuldaninhibit pancreatic lipase. Natural Product Sciences. 2003;9:38-43.

12. Cho KH, Kim YS, Bae HS, Moon SK, Jung WS, Park EK et al., Inhibitory effect of chunghyuldan on prostaglandin E2 and nitric oxide biosynthesis of lipopolysaccharide-induced RAW 264.7 cells. Biol. Pharm. Bull. 2004;27:1810-3.

13. Cho KH, Jung WS, Park SU, Moon SK, Kim YS, Bae HS. Clinical assessment on the safety of chunghyul-dan. J Korean Oriental Med. 2003; 24:45-50.

14. Cho KH, Kang HS, Jung WS, Park SU, Moon SK. Efficacy and safety of chunghyul-dan (qingwie-dan) in patients with hypercholesterolemia. Am J Chin Med. 2005;33:241-8.

15. Yun SP, Jung WS, Park SU, Moon SK, Ko CN, Cho KH et al. Anti-hypertensive effect of chunghyul- dan (qingxue-dan) on stroke patients with essential hypertension. Am J Chin Med. 2005; 33:357-64.

16. Agnoli A, Rapin Jr, Scapagnini V. Effects of Ginkgo biloba extract on organic cerebral impairment. Proceedings of the International Symposium. London: John Libbey & Company Ltd; 1985, p. 1-106.

17. Spinnewyn B, Blavet N, Clostre F. Effects of Gingko biloba extract on a cerebral ischemia model in gerbils. Presse Med. 1986;15:1511-5.

18. Kleijnen J and Knipschild P. Ginkgo biloba. Lancet. 1992;340:1136-9.

19. Francis V. Defeudis. Bilobalide and neuroprotection. Pharmacol. Res. 2002;46:565-8.

20. Hayakawa J, Noda N, Yamada S, Mikami E, Uno K, and Yakugadu Z. Studies on physical chemical quality evaluation of crude drugs preparations. III. Analysis of gardenia fruits and its preparations. Yakugaku Zasshi. 1986;105:996-1000.

21. Blois MS. Antioxidant determination by the use of a stable free radical. Nature. 1958;181:1199- 1200.

22. Okamura, H., Mimura, A., Yakou, Y., Niwano, M., Takahashi, Y.activity of tannins and flavonoids in Eucalyptus Phytochemistry. 1993;33: 557-61.

23. Amakura Y, Umino Y, Tsuji S, Ito H, Hatano T, Yoshida T et al. Constituents and their antioxidative effects in eucalyptus leaf extract used as a natural food additive. Food Chemistry. 2002;77:47-56.

24. Miki, M, Tamai H, Mino M, Yamamoto Y, Niki E. Free-radical chain oxidation of rat red blood cells by molecularand its inhibition by α-tocopherol. Arch. Biochem. Biophys. 1987;258:373-80.

25. Born GV and Cross MJ. The aggregation of blood platelets. J. Physiol. 1963;168:178-95.

26. Duhault J, Boulanger M, Beregi L, Sicot N, Bouvier F. 780 SE: A new type of hyperlipidemic agent. Comparative assay in rats. Atherosclerosis. 1976;23:63-72.

27. Kusama H, Nishiyama M, Ikeda S. Pharmacological investigation of bezafibrate, a hypolipidemic agent (I). Effect of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol. Japon. 1988;92:175-80.

28. Niiho H, Yamazaki T, Nakajima Y, Itoh H, Takeshita T, Kinjo J et al.: Pharmacological studies on Puerariae Flos. II. The effects of Puerariae Flos on alcohol-induced unusual metabolism and experimental liver injury in mice. Yakugaku Zasshi. 1990;110:604-11. Clin. Chem. 1974;20: 470-5.

29. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol.

30. Van Handel E and Zilversmit DB. Micromethod for the direct determination of serum triglycerides. J Lab Clin Med. 1957;50:152-7.

31. Mainard F and Madec Y. Cholesterol, phospholipid and apoB composition of LDL: Comparison of precipitation and ultracentrifugation methods. Ann. Biol. Clin. 1986;44:618-23.

32. Lopes-Virella MF, Stone P, Ellis S, Colwell JA.Cholesterol determination in high density lipoproteins separated by three different methods. Clin. Chem. 1977;23:822-4.

33. Twaij HA, Kery A, Al-Khazraji NK. Some pharmacological, toxicological and phytochemical investigations on Centaurea Phyllocephala. J. Ethnopharmacol. 1983;9:299-314.

34. SiesjoBK, Agardh C-D, Bengtsson F. Free radicals and brain damage. Cerebrovasc. Brain Metab. Rev. 1989;1:165-211.

35. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T.Ebselen in acute ischemic stroke: A placebo-controlled double-blind clinical trial. Ebselen Study group. Stroke 1998;29:12-7.

36. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke. 2001;32:675 -80.

37. Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plockinger U et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler. Thromb. Vasc. Biol.2005;25:1299-1303.

38. Weksler BB: Platelet function and antiplatelet therapy in ischemic cerebrovascular disease; in Barnett HJM (ed): Stroke: Pathophysiology, Diagnosis and Management. New York, Churchill Livingstone, 1992, pp 913-7.

39. Akyuz A, Bolayir E, Dener S, Topalkara K, Topaktas S. The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study. Eur J Neurol. 1999;6:57-61.

40. Danton GH, Prado R, Truettner J, Watson BD, Dietrich WD. Endothelial nitric oxide synthase pathophysiology after nonocclusive common carotid artery thrombosis in rats. J. Cereb. Blood Flow Metab. 2002;22:612-9.

41. Nieuwenhuis HK, Akkermen JWN, Houdijk WPM, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glucoprotein Ia. Nature. 1985;318:470-2.

42. Chinese Acute Stroke Trial (CAST) Collaborative Group. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-9.

43. Caro JJ and Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: The example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis). Clopidogrel versus Aspirin in patients at risk of ischemic events. Am J Med. 1999;107:568-72.

44. Antithrombotic Trialists’Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.

45. Friedman M and Byers SO. The mechanism resp- onsible for the hypercholesteremia induced by Triton WR-1339. J. Exp. Med. 1953;97:117-30.

46. Hirsch RL and Kellner A. The pathogenesis of hyperlipidemia induced by means of surfaceactive agents. I. Increased total body cholesterol in mice given Triton WR-1339 parenterally. J. Exp. Med. 1956;104:1-13.

47. Toda T and Oku H. Effect of medium-chain fatty acids on cholesterolemia and atherosclerosis in Japanese quails. Nutr. Res. 1995;15:99-113.

48. Okawa M, Kinjo J, Nohara T, Ono M. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. Biol. Pharm. Bull. 2001;24: 1202-5.

49. Huang WH, Lee AR, Yang CH. Antioxidative and anti-Inflammatory activities of polyhydroxyflavonoids of Scutellaria Baicalensis GEORGI. Biosci Biotechnol. Biochem. 2006 ;70:2371-80.

50. Yokozawa T, Ishide A, Cho EJ, Nakagawa T. The effects of Coptidis Rhizoma extract on a hypercholesterolemic animal model. Phytomedicine. 2003;10:17-22.

51. Chang GT, Min SY, Kim JH, Kim SH, Kim JK, Kim CH. Anti-thrombic activity of Korean herbal medicine, Dae-Jo-Whan and its herbs. Vascul. Pharmacol. 2005;43:283-8.

52. Lee IA, Lee JH, Baek NI, Kim DH Antihyperlipidemic effect of crocin isolated from the fructus of Gardenia Jasminoides and its metabolite Crocetin. Biol. Pharm. Bull. 2005;28:2106-10.

53. Yokozawa T, Chen CP, Tanaka T. Direct scavenging of nitric oxide by traditional crude drugs. Phytomedicine. 2000;6:453-63.

54. Hibatallah J, Carduner C, Poelman MC. In-vivo and in-vitro assessment of the free-radical-scavenger activity of Ginkgo flavone glycosides at high concentration. J. Pharm. Pharmacol. 1999; 51:1435-40.

55. Dutta-Roy AK, Gordon MJ, Kelly C, Hunter K, Crosbie L, Knight-Carpentar T et al. Inhibitory effect of Ginkgo biloba extract on human platelet aggregation. Platelets. 1999;10:298-305.

56. Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract (Egb 761) inhibits betaamyloid production by lowering free cholesterol levels. J. Nutr. Biochem. 2004;15:749-56.

57. Kudolo GB, Delaney D, Blodgett J. Short-term oral ingestion of Ginkgo biloba extract (EGb 761) reduces malondialdehyde levels in washed platelets of type 2 diabetic subjects. Diabetes Res. Clin. Pract. 2005;68:29-38.

58. Benfante R, Yano K, Hwang LJ, Curb JD, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke. 1994;25:814 -20.

59. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001; 103:387-92.

60. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med.. 1989;320:904-10.

61. Plutzky J and Ridker PM. Statins for stroke: the second story? Circulation. 2001;103:348-50.

62. Amarenco P, Labreuche J,Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systemic review and up-to-date meta-analysis. Stroke. 2004;35:2902-9.

63. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range or initial cholesterol levels. N. Engl. J. Med. 1998; 339:1349-57. (866)